EVFM News and Press, Evofem Biosciences Inc. From 12/12/23

2023-12-12 08:59:04 ET More on Evofem Biosciences Evofem Biosciences expects to see third consecutive quarter of growth Evofem says no Phexxi generic until 2033 after company amends ANDA Financial information for Evofem Biosciences For further details see: ...

Evofem posted $13.4 million in net sales of Phexxi for the first nine months of 2023; Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031 Aditxt, Inc. ( ...

Evofem Biosciences Inc. (EVFM) is expected to report for quarter end 2023-09-30

2023-11-14 06:58:57 ET More on Evofem Biosciences Evofem Biosciences expects to see third consecutive quarter of growth Evofem says no Phexxi generic until 2033 after company amends ANDA Financial information for Evofem Biosciences For further details see: ...

Evofem Biosciences Announces Financial Results for the Third Quarter of 2023 PR Newswire — On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of ...

2023-10-24 09:14:28 ET More on Evofem Biosciences Evofem says no Phexxi generic until 2033 after company amends ANDA Financial information for Evofem Biosciences For further details see: Evofem Biosciences expects to see third consecutive quarter of growth

Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023 PR Newswire — On track to achieve third consecutive year of net product sales growth — — Third consecutive quarter of favorable net product sales- to- sales and ma...

Evofem to Participate in the Virtual Investor Ask the CEO Conference PR Newswire -- Live moderated video webcast with members of Evofem management team on Tuesday, October 24th at 10:00 AM ET -- SAN DIEGO , Oct. 13, 2023 /PRNewswire/ -- Evofem B...

Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire PR Newswire -- Padagis Determined They Will Not Challenge the Phexxi Patents -- -- Evofem Has Phexxi Patent Protection Through 203...

Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor PR Newswire -- Investor withdraws March 2023 Notice of Default -- -- Notes are no longer convertible to shares of common stock, removing potential dilution from the previously...